TLPH241220P5000
- 0.00
- 0.000.00%
Talphera Newsroom
Express News | Talphera Inc - Receives Notice of Non-Compliance With Nasdaq Equity Requirement
Maxim Group Maintains Talphera(TLPH.US) With Buy Rating, Maintains Target Price $3
Talphera's Promising Prospects: Buy Rating Affirmed Amidst Strategic Advancements in Anticoagulant Development
Talphera Third Quarter 2024 Earnings: US$0.13 Loss per Share (Vs US$0.085 Loss in 3Q 2023)
US Manufacturing Index Rises To 43, Highest Since 2020
H.C. Wainwright Maintains Talphera(TLPH.US) With Buy Rating, Maintains Target Price $6
Optimistic Buy Rating for Talphera Driven by Promising NEPHRO CRRT Study Progress and Niyad's Potential
Talphera Shares Are Trading Lower. The Company Reported Q3 Financial Results.
Talphera, Inc. (TLPH) Q3 2024 Earnings Call Transcript Summary
Talphera, Inc. (TLPH) Q3 2024 Earnings Call Transcript
Talphera | 10-Q: Q3 2024 Earnings Report
Talphera | 8-K: Talphera Announces Third Quarter 2024 Financial Results and Provides Corporate Update
AcelRx Pharmaceuticals GAAP EPS of -$0.13 Beats by $0.07
Talphera Q3 2024 GAAP EPS $(0.13) Beats $(0.20) Estimate
Press Release: Talphera Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Here Are the Major Earnings After the Close Today
Earnings Scheduled For November 13, 2024
AcelRx Pharmaceuticals Q3 2024 Earnings Preview
An Overview of Talphera's Earnings
Earnings Preview: Talphera to Report Financial Results Post-market on November 13
$Talphera(TLPH.US)$ is scheduled to release its financial results post-market on November 13 ET. Earnings PreviewAnalysts estimate $Talphera(TLPH.US)$ to post revenue of USD0 for 2024Q3, YoY-100%;